GlassScriptPhysician profile
Heather Ingram
NPI 1902405947
$13,395.58
in general payments reported to CMS, 2019-2025
58 companies · $4,697 in 2025
The $4,697 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,286 · 2022: $1,143 · 2023: $1,949 · 2024: $4,322 · 2025: $4,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $150 · Education: $26.80 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,764.77 |
| Consulting Fee | $150.00 |
| Education | $26.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,615.96 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,172.99 | 2021-2025 | |
| Neurelis, INC. | $1,097.54 | 2021-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $739.22 | 2023-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $720.62 | 2023-2025 | Gocovri, Apokyn, Apokyn |
| Lundbeck LLC | $694.55 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $623.12 | 2021-2025 | |
| Biogen, INC. | $519.14 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Pfizer INC. | $461.24 | 2023-2025 | |
| Genentech USA, INC. | $397.83 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Neurocrine Biosciences, INC. | $366.17 | 2022-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $364.09 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Jazz Pharmaceuticals INC. | $312.83 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $285.63 | 2021-2025 | Nuplazid |
| Argenx US, INC. | $283.21 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.